offline
Baudax Bio Inc. Nasdaq: BXRX <= Kennt die jemand, ist wer investiert? 
https://seekingalpha.com/article/4325034-baudax-bio-recros-spin-out-is-buy-prices
Baudax Bio is a recent spin-out of Recro Pharma's Acute Care Segment and is already preparing for Ajenso's PDUFA date on February 20th.
If approved, Ajenso will be a niche acute care product that is in a growing $6B market. I believe this opportunity makes BXRX a buy at these prices.
I discuss some of the tickers downside risks and how I plan to manage my spin-out position around the PDUFA.
BXRX Stock derzeit zu $8.44+0.06 (+0.66%)
Morgen wissen wir mehr.
https://seekingalpha.com/article/4325034-baudax-bio-recros-spin-out-is-buy-prices
Baudax Bio is a recent spin-out of Recro Pharma's Acute Care Segment and is already preparing for Ajenso's PDUFA date on February 20th.
If approved, Ajenso will be a niche acute care product that is in a growing $6B market. I believe this opportunity makes BXRX a buy at these prices.
I discuss some of the tickers downside risks and how I plan to manage my spin-out position around the PDUFA.
BXRX Stock derzeit zu $8.44+0.06 (+0.66%)
Morgen wissen wir mehr.
